1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one has been researched along with monocrotaline in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Badejo, AM; Bhartiya, M; Haider, U; Kadowitz, PJ; Murthy, SN; Nossaman, BD; Pankey, EA; Stasch, JP | 1 |
1 other study(ies) available for 1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one and monocrotaline
Article | Year |
---|---|
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Benzoates; Biphenyl Compounds; Guanylate Cyclase; Heme; Hydrocarbons, Fluorinated; Hypertension, Pulmonary; Male; Monocrotaline; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroprusside; Oxadiazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2011 |